Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 14.704
1.
Pan Afr Med J ; 47: 114, 2024.
Article En | MEDLINE | ID: mdl-38828426

Chronic kidney disease (CKD) is commonly complicated by anemia. Treating dialysis-dependent patients with anemia, including daprodustat and other inhibitors of prolyl hydroxylase of hypoxia-inducible factor, recombinant human erythropoietin (rhEPO), and iron supplements. We conducted this study to test our postulation; daprodustat is superior to rhEPO and other conventional treatments respecting efficacy and safety parameters. We made systematic search through PubMed, Web of Science, Scopus, and Cochrane. Seven unique trials were eventually included for systematic review; six of them with a sample size of 759 patients entered our network meta-analysis (NMA). Daprodustat 25-30 mg was associated with the greatest change in serum hemoglobin (MD=1.86, 95%CI= [1.20; 2.52]), ferritin (MD= -180.84, 95%CI= [-264.47; -97.20]), and total iron binding capacity (TIBC) (MD=11.03, 95%CI= [3.15; 18.92]) from baseline values. Dialysis-dependent patients with anemia had a significant increment in serum Hemoglobin and TIBC and a reduction in serum ferritin, in a dose-dependent manner, when administered daprodustat.


Anemia , Barbiturates , Ferritins , Glycine , Hemoglobins , Renal Dialysis , Renal Insufficiency, Chronic , Humans , Anemia/drug therapy , Anemia/etiology , Hemoglobins/analysis , Hemoglobins/metabolism , Renal Insufficiency, Chronic/therapy , Renal Insufficiency, Chronic/complications , Glycine/analogs & derivatives , Glycine/administration & dosage , Ferritins/blood , Barbiturates/administration & dosage , Network Meta-Analysis , Erythropoietin/administration & dosage , Recombinant Proteins/administration & dosage , Dose-Response Relationship, Drug , Iron/administration & dosage
2.
Curr Opin Oncol ; 36(4): 223-232, 2024 Jul 01.
Article En | MEDLINE | ID: mdl-38842015

PURPOSE OF REVIEW: The increased use of i.v. iron in the treatment of cancer-associated anemia raises concerns about its risk of infectious complications. High levels of circulating iron could increase the risk of infection by compromising natural defence mechanisms and promoting pathogen growth. Since the risk of infection is particularly high in the oncological population, we have examined whether the use of i.v. iron increases the risk of infectious complications among cancer patients. FINDINGS: Among 18 randomized trials in our systematic review, only 8 reported infectious complications, with no significant difference linked to the type of i.v. iron preparation. Two trials showed a statistically significant increase in infectious complications, one trial found a lower risk, while the remaining 5 reported no significant difference. Our meta-analysis revealed a numerical increase in infectious complications in the i.v. iron group, but the lack of statistical significance and significant heterogeneity among the trials limit definitive conclusions on the actual infection risk. SUMMARY: Our findings suggest some increased risk in infectious complications after the administration of i.v. iron for cancer associated anaemia. However, i.v. iron therapy appears generally safe and effective in cancer-associated anaemia.


Anemia , Iron , Neoplasms , Humans , Neoplasms/complications , Neoplasms/drug therapy , Anemia/drug therapy , Anemia/etiology , Iron/administration & dosage , Randomized Controlled Trials as Topic , Infections/etiology
3.
South Med J ; 117(6): 311-315, 2024 Jun.
Article En | MEDLINE | ID: mdl-38830584

Mesenteric angina has a high mortality rate. Occlusion of the superior mesenteric artery is the most common cause. Increasingly, it is managed endovascularly instead of by open revascularization. Despite the lower risk of complications in minimally invasive procedures, it is important to be mindful of long-term sequelae of minor complications. Patient education regarding risks and complications is paramount for better clinical outcomes. The risks of transbrachial angiography procedures are low. Postprocedural vigilance for interventionists and written educational advice to patients are paramount in all minimally invasive endovascular procedures, especially because most of these patients with a complication require urgent operative correction.


Anemia , Humans , Anemia/etiology , Anemia/therapy , Anemia/diagnosis , Median Neuropathy/etiology , Median Neuropathy/diagnosis , Male , Mesenteric Artery, Superior/diagnostic imaging
4.
Support Care Cancer ; 32(7): 415, 2024 Jun 07.
Article En | MEDLINE | ID: mdl-38847977

PURPOSE: Anemia is relatively common in cancer patients, and is associated with poor survival in patients with various malignancies. However, how anemia would affect prognosis and response to neoadjuvant chemotherapy (NAC) in osteosarcoma (OS) is still without substantial evidence. METHODS: We retrospectively analysed 242 patients with stage II OS around the knee joint in our institute. Changed hemoglobin (Hb) levels (before and after NAC) were recorded to assess the prognostic value in DFS (disease-free survival) and tumor response to NAC. Univariate and multivariate analyses were conducted to identify prognostic factors related with outcome in OS patients. RESULTS: The mean Hb level significantly decreased after NAC (134.5 ± 15.3 g/L vs. 117.4 ± 16.3 g/L). The percentage of mild (21%), moderate (4.2%) and severe (0%) anemia patients markedly increased after NAC: 41%, 24% and 4.1% respectively. There was higher percentage of ≥ 5% Hb decline in patients with tumor necrosis rate < 90% (141 out of 161), compared with those with tumor necrosis rate ≥ 90% (59 out of 81). Further univariate and survival analysis demonstrated that Hb decline had a significant role in prediction survival in OS patients. Patients with ≥ 5% Hb decline after NAC had an inferior DFS compared with those with < 5% Hb decline. CONCLUSION: In osteosarcoma, patients with greater Hb decrease during neoadjuvant treatment were shown to have worse DFS and a poorer response to NAC than those without. Attempts to correct anemia and their effects on outcomes for osteosarcoma patients should be explored in future studies.


Anemia , Bone Neoplasms , Hemoglobins , Knee Joint , Neoadjuvant Therapy , Osteosarcoma , Humans , Osteosarcoma/drug therapy , Osteosarcoma/mortality , Retrospective Studies , Male , Female , Neoadjuvant Therapy/methods , Hemoglobins/analysis , Adult , Prognosis , Anemia/etiology , Adolescent , Bone Neoplasms/drug therapy , Bone Neoplasms/mortality , Young Adult , Child , Knee Joint/pathology , Disease-Free Survival , Middle Aged , Multivariate Analysis , Chemotherapy, Adjuvant/methods , Severity of Illness Index
5.
Zhonghua Xue Ye Xue Za Zhi ; 45(3): 290-293, 2024 Mar 14.
Article Zh | MEDLINE | ID: mdl-38716602

Myelodysplastic syndromes is a heterogeneous group of myeloid neoplastic disorders originating from hematopoietic stem cells and manifesting as pathological bone marrow hematopoiesis and a high risk of transformation to acute myeloid leukemia. In low-risk patients, the therapeutic goal is to improve hematopoiesis and quality of life. Roxadustat is the world's first oral small-molecule hypoxia-inducible factor prolyl hydroxylase inhibitor, which, unlike conventional erythropoietin, corrects anemia through various mechanisms. In this study, we retrospectively analyzed the changes in anemia, iron metabolism, lipids and inflammatory indexes in patients with low-risk myelodysplastic syndromes to evaluate its therapeutic efficacy and safety, and to provide theoretical and practical data for the application of roxadustat in myelodysplastic syndromes.


Anemia , Isoquinolines , Myelodysplastic Syndromes , Humans , Anemia/etiology , Anemia/drug therapy , Glycine/analogs & derivatives , Glycine/therapeutic use , Hypoxia-Inducible Factor-Proline Dioxygenases/antagonists & inhibitors , Isoquinolines/therapeutic use , Isoquinolines/administration & dosage , Myelodysplastic Syndromes/drug therapy , Prolyl-Hydroxylase Inhibitors/therapeutic use , Retrospective Studies
6.
Nihon Yakurigaku Zasshi ; 159(3): 157-159, 2024.
Article Ja | MEDLINE | ID: mdl-38692879

Anemia in chronic kidney disease (CKD) occurs due to insufficient production of erythropoietin to compensate for the decrease in hemoglobin. Anemia in CKD has traditionally been treated with periodic injections of erythropoiesis-stimulating agents (ESAs), which are recombinant human erythropoietin preparations. Although ESA improved anemia in CKD and dramatically improved the quality of life of patients, there are some patients who are hyporesponsive to ESA, and the use of large doses of ESA in these patients may have a negative impact on patient prognosis. Currently, HIF prolyl hydroxylase (HIF-PH) inhibitors have been approved in Japan as a new treatment for anemia in CKD. HIF-PH inhibitors activate HIF and promote the production of endogenous erythropoietin. The 2019 Nobel Prize in Physiology or Medicine was awarded for groundbreaking research that uncovered the HIF pathway. Because HIF-PH inhibitors improve both erythropoietin production and iron metabolism, they are expected to be effective in treating ESA hyporesponsiveness and solve the inconvenience of injectable preparations. On the other hand, its effects are systemic and multifaceted, and long-term effects must be closely monitored.


Anemia , Humans , Anemia/drug therapy , Anemia/etiology , Renal Insufficiency, Chronic/drug therapy , Renal Insufficiency, Chronic/metabolism , Hypoxia-Inducible Factor-Proline Dioxygenases/antagonists & inhibitors , Hypoxia-Inducible Factor-Proline Dioxygenases/metabolism , Erythropoietin/metabolism
7.
G Ital Nefrol ; 41(2)2024 Apr 29.
Article It | MEDLINE | ID: mdl-38695231

Introduction. Patients undergoing chronic haemodialysis (HD) treatment have an 8-10 times higher risk of experiencing stroke events and developing cognitive impairment. The high vascular stress they are subjected to may be the basis for the development of vascular dementia (VaD). Objective. The aim of the study is to investigate the executive functions, typically impaired in VaD, of patients undergoing chronic haemodialysis treatment. Method. HD patients were recruited from the U.O.C. of Nephrology and Dialysis (ASP Ragusa). Risk factors for VaD were collected and then the Frontal Assessment Battery (FAB) was administered. Results. 103 HD patients were included (males = 63%, age 66 ± 14 years). Risk factors for VaD included a high percentage of patients with anaemia (93%), hypertension (64%) and coronary artery disease (68%). The cognitive data obtained via FAB show a percentage of 55% deficit scores. All risk factors found a significant association with cognitive scores. Anemia, hypertension, intradialytic hypotension, coronary artery disease, and homocysteine are negative predictors of executive function integrity. Conclusions. More than half of the patients had deficit scores on the FAB. Reduced cognitive flexibility, high sensitivity to interference, poor inhibitory control and impaired motor programming with the dominant hand were evident. In conclusion, a marked impairment of the executive functions, generally located in the frontal lobes of the brain, was detected in the HD patient, which could be a symptom of a dementia of a vascular nature.


Dementia, Vascular , Executive Function , Renal Dialysis , Humans , Renal Dialysis/adverse effects , Aged , Female , Male , Dementia, Vascular/etiology , Middle Aged , Risk Factors , Anemia/etiology , Hypertension/etiology
8.
Trials ; 25(1): 305, 2024 May 06.
Article En | MEDLINE | ID: mdl-38711052

BACKGROUND: To analyze the perioperative bleeding and hidden blood loss (HBL) of sacroiliac screw minimally invasive treatment of pelvic posterior ring injury and explore the influential factors of HBL after operation for providing reference for clinical treatment. METHOD: A retrospective analysis was conducted on data from 369 patients with posterior pelvic ring injuries treated with sacroiliac screws internal fixation at our hospital from January 2015 to January 2022. The research was registered in the Chinese Clinical Trial Registry in July 2022 (ChiCTR2200061866). The total blood loss (TBL) and HBL of patients were counted, and the factors such as gender, age, and surgical duration were statistically analyzed. The influential factors of HBL were analyzed by multiple linear regression. RESULTS: The TBL was 417.96 ± 98.05 ml, of which the visible blood loss (VBL) was 37.00 ± 9.0 ml and the HBL was 380.96 ± 68.8 ml. The HBL accounted for 91.14 ± 7.36% of the TBL. Gender, surgical duration, fixed position, and fixed depth had significant effects on the HBL (P < 0.05). CONCLUSIONS: The HBL was the main cause of anemia after minimally invasive treatment of posterior pelvic ring injury with a sacroiliac screw. Gender, surgical duration, fixed position, and fixed depth were closely related to the occurrence of HBL. In clinical treatment, we should consider these influential factors and take effective measures to reduce the impact of HBL on patients.


Blood Loss, Surgical , Bone Screws , Fracture Fixation, Internal , Pelvic Bones , Humans , Male , Female , Retrospective Studies , Pelvic Bones/injuries , Pelvic Bones/surgery , Adult , Middle Aged , Fracture Fixation, Internal/adverse effects , Fracture Fixation, Internal/instrumentation , Fracture Fixation, Internal/methods , Treatment Outcome , Risk Factors , Young Adult , Fractures, Bone/surgery , Fractures, Bone/diagnostic imaging , Time Factors , China , Aged , Minimally Invasive Surgical Procedures/methods , Anemia/etiology
9.
Bratisl Lek Listy ; 125(6): 392-398, 2024.
Article En | MEDLINE | ID: mdl-38757598

OBJECTIVES: This study aims to determine the malnutrition status among Vietnamese patients newly diagnosed with gastric cancer (GC). BACKGROUND: GC remains the top rank of common and deadly diseases. With limited clinical manifestation, most GC patients were diagnosed at late stages when tumor is not radically resected. Malnutrition was associated with poor prognosis of GC, such as prolonged hospitalization, limited treatment efficacy and low survival rate. METHODS: The cross-sectional descriptive study recruited 77 patients newly diagnosed with GC and 90 healthy individuals (HC). The data used for this study were approved by the local Ethical Committee. The data were analysed on STATA 14.0 and GraphPad Prism 8.0. RESULTS: We observed the male dominant distribution in GC cohort and over 65% of GC were firstly diagnosed at advanced stages (III and IV). Anemia was detected in about 50% of GC patients. Hyponutrition was prevalent in newly diagnosed GC. We found the decreased tendency of anemia related indexes from HC to early stages (I and II) and advanced stages (III and IV) of GC patients. CONCLUSION: Anemia and hypoproteinemia occurred frequently among Vietnamese newly diagnosed GC. The nutrition therapy would benefit GC patients (Tab. 4, Fig. 4, Ref. 20).


Anemia , Malnutrition , Stomach Neoplasms , Humans , Stomach Neoplasms/diagnosis , Male , Female , Cross-Sectional Studies , Middle Aged , Vietnam/epidemiology , Anemia/diagnosis , Anemia/etiology , Malnutrition/diagnosis , Malnutrition/epidemiology , Aged , Adult , Neoplasm Staging
10.
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi ; 38(5): 570-575, 2024 May 15.
Article Zh | MEDLINE | ID: mdl-38752243

Objective: To explore the impact of anemia on the incidence of perioperative lower limb deep vein thrombosis (DVT) in patients undergoing total hip arthroplasty (THA). Methods: A retrospective analysis was conducted on clinical data of 1 916 non-fracture patients who underwent THA between September 2015 and December 2021, meeting the selection criteria. Among them, there were 811 male and 1 105 female patients, aged between 18 and 94 years with an average of 59.2 years. Among the patients, 213 were diagnosed with anemia, while 1 703 were not. Preoperative DVT was observed in 55 patients, while 1 861 patients did not have DVT preoperatively (of which 75 patients developed new-onset DVT postoperatively). Univariate analysis was performed on variables including age, gender, body mass index (BMI), diabetes, hypertension, history of tumors, history of thrombosis, history of smoking, revision surgery, preoperative D-dimer positivity (≥0.5 mg/L), presence of anemia, operation time, intraoperative blood loss, transfusion requirement, and pre- and post-operative levels of red blood cells, hemoglobin, hematocrit, and platelets. Furthermore, logistic regression was utilized for multivariate analysis to identify risk factors associated with DVT formation. Results: Univariate analysis showed that age, gender, hypertension, revision surgery, preoperative levels of red blood cells, preoperative hemoglobin, preoperative D-dimer positivity, and anemia were influencing factors for preoperative DVT ( P<0.05). Further logistic regression analysis indicated that age (>60 years old), female, preoperative D-dimer positivity, and anemia were risk factors for preoperative DVT ( P<0.05). Univariate analysis also revealed that age, female, revision surgery, preoperative D-dimer positivity, anemia, transfusion requirement, postoperative level of red blood cells, and postoperative hemoglobin level were influencing factors for postoperative new-onset DVT ( P<0.05). Further logistic regression analysis indicated that age (>60 years old), female, and revision surgery were risk factors for postoperative new-onset DVT ( P<0.05). Conclusion: The incidence of anemia is higher among patients with preoperative DVT for THA, and anemia is an independent risk factor for preoperative DVT occurrence in THA. While anemia may not be an independent risk factor for THA postoperative new-onset DVT, the incidence of anemia is higher among patients with postoperative new-onset DVT.


Anemia , Arthroplasty, Replacement, Hip , Lower Extremity , Postoperative Complications , Venous Thrombosis , Humans , Venous Thrombosis/etiology , Venous Thrombosis/epidemiology , Arthroplasty, Replacement, Hip/adverse effects , Female , Male , Middle Aged , Retrospective Studies , Aged , Anemia/epidemiology , Anemia/etiology , Incidence , Risk Factors , Lower Extremity/blood supply , Adult , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Aged, 80 and over , Adolescent , Perioperative Period , Young Adult , Fibrin Fibrinogen Degradation Products/analysis , Fibrin Fibrinogen Degradation Products/metabolism
12.
BMC Surg ; 24(1): 156, 2024 May 16.
Article En | MEDLINE | ID: mdl-38755612

PURPOSE: Hypoalbuminemia and anemia are commonly observed indications for one anastomosis gastric bypass (OAGB) reversal and remain significant concerns following the procedure. Sufficient common channel limb length (CCLL) is crucial to minimize nutritional complications. However, limited literature exists regarding the impact of CCLL on OAGB outcomes. This study aimed to assess the effect of CCLL on weight loss and nutritional status in patients who underwent OAGB. METHODS: A prospective cohort study was conducted from August 2021 to July 2022, involving 64 patients with a body mass index of 40-50 kg/m2. The standardized length of the biliopancreatic limb (BPLL) for all patients in this study was set at 175 cm. Additionally, the measurement of the common channel limb length (CCLL) was performed consistently by the same surgeon for all included patients. RESULTS: The mean age and BMI of the patients were 39.91 ± 10.03 years and 43.13 ± 2.43 kg/m2, respectively, at the time of surgery. There was a statistically significant negative correlation between CCLL and percent total weight loss (%TWL) at the 12-month mark after OAGB (P = 0.02). Hypoalbuminemia was observed in one patient (1.6%), while anemia was present in 17 patients (26.6%) at the one-year follow-up. Statistical analysis revealed no significant difference in the incidence of anemia and hypoalbuminemia between patients with CCLL < 4 m and those with CCLL ≥ 4 m. CONCLUSION: A CCLL of 4 m does not appear to completely prevent nutritional complications following OAGB. However, maintaining a CCLL of at least 4 m may be associated with a reduced risk of postoperative nutritional deficiencies.


Gastric Bypass , Malnutrition , Postoperative Complications , Humans , Gastric Bypass/methods , Gastric Bypass/adverse effects , Female , Male , Malnutrition/prevention & control , Malnutrition/etiology , Prospective Studies , Adult , Postoperative Complications/prevention & control , Postoperative Complications/etiology , Postoperative Complications/epidemiology , Middle Aged , Weight Loss , Obesity, Morbid/surgery , Hypoalbuminemia/etiology , Anemia/prevention & control , Anemia/etiology , Nutritional Status , Body Mass Index , Anastomosis, Surgical/methods
13.
Clin Transplant ; 38(6): e15367, 2024 Jun.
Article En | MEDLINE | ID: mdl-38809215

INTRODUCTION: The prevalence of iron deficiency and anemia in the setting of modern-day maintenance immunosuppression in pediatric heart transplant (HTx) recipients is unclear. The primary aim was to determine the prevalence of iron deficiency (serum ferritin < 30 ng/mL ± transferrin saturation < 20%) and anemia per World Health Organization diagnostic criteria and associated risk factors. METHODS: Single-center, cross-sectional analysis of 200 consecutive pediatric HTx recipients (<21 years old) from 2005 to 2021. Data were collected at 1-year post-HTx at the time of annual protocol biopsy. RESULTS: Median age at transplant was 3 years (IQR .5-12.2). The median ferritin level was 32 ng/mL with 46% having ferritin < 30 ng/mL. Median transferrin saturation (TSAT) was 22% with 47% having TSAT < 20%. Median hemoglobin was 11 g/dL with 54% having anemia. Multivariable analysis revealed lower absolute lymphocyte count, TSAT < 20%, and estimated glomerular filtration rate <75 mL/min/1.73 m2 were independently associated with anemia. Ferritin < 30 ng/mL in isolation was not associated with anemia. Ferritin < 30 ng/mL may aid in detecting absolute iron deficiency while TSAT < 20% may be useful in identifying patients with functional iron deficiency ± anemia in pediatric HTx recipients. CONCLUSION: Iron deficiency and anemia are highly prevalent in pediatric HTx recipients. Future studies are needed to assess the impact of iron deficiency, whether with or without anemia, on clinical outcomes in pediatric HTx recipients.


Anemia, Iron-Deficiency , Heart Transplantation , Humans , Heart Transplantation/adverse effects , Male , Female , Cross-Sectional Studies , Child , Prevalence , Child, Preschool , Follow-Up Studies , Risk Factors , Prognosis , Anemia, Iron-Deficiency/epidemiology , Anemia, Iron-Deficiency/diagnosis , Anemia, Iron-Deficiency/etiology , Postoperative Complications/epidemiology , Postoperative Complications/diagnosis , Postoperative Complications/etiology , Postoperative Complications/blood , Iron Deficiencies , Infant , Adolescent , Anemia/epidemiology , Anemia/etiology , Anemia/diagnosis , Transplant Recipients/statistics & numerical data , Graft Rejection/etiology , Graft Rejection/epidemiology , Graft Rejection/blood , Graft Rejection/diagnosis
15.
Pan Afr Med J ; 47: 95, 2024.
Article En | MEDLINE | ID: mdl-38799192

Abdominal pregnancy is a rare form of ectopic pregnancy (accounting for 1% of all ectopic pregnancies). Depending on gestational age and its location various symptoms and signs may be exhibited. This study aimed to report a case of abdominal pregnancy occurring in the Morrison Pouch with a primary presentation of right upper quadrant pain and to highlight complications that may arise in the management of abdominal pregnancy located in the Morrison Pouch. A 22-year pregnant woman at gestation of 22 weeks presented with a right upper quadrant mass and pain. Ultrasound examination revealed a live extrauterine singleton at Morrison Pouch, full blood count showed severe anemia. The patient received a blood transfusion in seven days and underwent emergency laparotomy after experiencing sudden acute internal hemorrhage but died a few hours post laparotomy due to hemorrhagic shock. Abdominal pregnancy carries a high risk of maternal hemorrhage as described in this case.


Abdominal Pain , Laparotomy , Pregnancy, Abdominal , Humans , Female , Pregnancy , Young Adult , Abdominal Pain/etiology , Laparotomy/methods , Pregnancy, Abdominal/diagnosis , Pregnancy, Abdominal/surgery , Blood Transfusion , Anemia/etiology , Anemia/diagnosis , Shock, Hemorrhagic/etiology , Fatal Outcome , Hemorrhage/etiology
16.
J Nephrol ; 37(3): 753-767, 2024 Apr.
Article En | MEDLINE | ID: mdl-38705934

Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are new drugs developed for the treatment of anemia associated with chronic kidney disease (CKD). This class of drugs stimulates endogenous erythropoietin production and, at the same time, improves iron absorption and mobilization of iron stores (less evident with daprodustat, vadadustat and enarodustat). Several studies have been published in the last few years showing that these agents are not inferior to standard therapy in correcting anemia associated with CKD. The efficacy of HIF-PHIs is coupled with a safety profile comparable to that of standard erythropoiesis stimulating agent (ESA) treatment. However, studies with HIF-PHIs were not long enough to definitively exclude the impact of new drugs on adverse events, such as cancer, death and possibly cardiovascular events, that usually occur after a long follow-up period. Kidney Disease: Improving Global Outcomes (KDIGO) recently reported the conclusions of the Controversies Conference on HIF-PHIs held in 2021. The goal of the present position paper endorsed by the Italian Society of Nephrology is to better adapt the conclusions of the latest KDIGO Conference on HIF-PHIs to the Italian context by reviewing the efficacy and safety of HIF-PHIs as well as their use in subpopulations of interest as emerged from more recent publications not discussed during the KDIGO Conference.


Anemia , Hypoxia-Inducible Factor-Proline Dioxygenases , Nephrology , Renal Insufficiency, Chronic , Humans , Renal Insufficiency, Chronic/complications , Anemia/drug therapy , Anemia/etiology , Nephrology/standards , Hypoxia-Inducible Factor-Proline Dioxygenases/antagonists & inhibitors , Consensus , Hematinics/therapeutic use , Italy , Prolyl-Hydroxylase Inhibitors/therapeutic use , Societies, Medical
18.
Med Sci Monit ; 30: e943126, 2024 May 05.
Article En | MEDLINE | ID: mdl-38704632

BACKGROUND Severe anemia caused by hemorrhoidal hematochezia is typically treated preoperatively with reference to severe anemia treatment strategies from other etiologies. This retrospective cohort study included 128 patients with hemorrhoidal severe anemia admitted to 3 hospitals from September 1, 2018, to August 1, 2023, and aimed to evaluate preoperative blood transfusion requirements. MATERIAL AND METHODS Of 5120 patients with hemorrhoids, 128 (2.25%; male/female: 72/56) experienced hemorrhoidal severe anemia, transfusion, and Milligan-Morgan surgery. Patients were categorized into 2 groups based on their preoperative hemoglobin (PHB) levels after transfusion: PHB ≥70 g/L as the liberal-transfusion group (LG), and PHB <70 as the restrictive-threshold group (RG). The general condition, bleeding duration, hemoglobin level on admission, transfusion volume, length of stay, immune transfusion reaction, surgical duration, and hospitalization cost were compared between the 2 groups. RESULTS Patients with severe anemia (age: 41.07±14.76) tended to be younger than those with common hemorrhoids (age: 49.431±15.59 years). The LG had a significantly higher transfusion volume (4.77±2.22 units), frequency of immune transfusion reactions (1.22±0.58), and hospitalization costs (16.69±3.31 thousand yuan) than the RG, which had a transfusion volume of 3.77±2.09 units, frequency of immune transfusion reactions of 0.44±0.51, and hospitalization costs of 15.00±3.06 thousand yuan. Surgical duration in the LG (25.69±14.71 min) was significantly lower than that of the RG (35.24±18.72 min). CONCLUSIONS Patients with hemorrhoids with severe anemia might require a lower preoperative transfusion threshold than the currently recognized threshold, with an undifferentiated treatment effect and additional benefits.


Anemia , Blood Transfusion , Hemorrhoids , Preoperative Care , Humans , Male , Female , Retrospective Studies , Anemia/therapy , Anemia/etiology , Blood Transfusion/methods , Middle Aged , Adult , Hemorrhoids/surgery , Hemorrhoids/complications , Preoperative Care/methods , Hemoglobins/analysis , Hemoglobins/metabolism , Length of Stay , Gastrointestinal Hemorrhage/surgery , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/therapy , Aged
20.
Saudi Med J ; 45(5): 495-501, 2024 May.
Article En | MEDLINE | ID: mdl-38734423

OBJECTIVES: To investigate the prevalence of hematologic findings and the relationship between hemogram parameters and brucellosis stages in patients. METHODS: This multi-center study included patients older than 16 years of age who were followed up with a diagnosis of brucellosis. Patients' results, including white blood cell, hemoglobin, neutrophil, lymphocyte, monocyte, mean platelet volume, platelet and eosinophil counts were analyzed at the initial diagnosis. RESULTS: In this study 51.3% of the patients diagnosed with brucellosis were male. The age median was 45 years for female and 41 years for male. A total of 55.1% of the patients had acute brucellosis, 28.2% had subacute, 7.4% had chronic and 9% had relapse. The most common hematologic findings in brucellosis patients were anemia (25.9%), monocytosis (15.9%), eosinopenia (10.3%), and leukocytosis (7.1%). Pancytopenia occurred in 0.8% of patients and was more prominent in the acute phase. The acute brucellosis group had lower white blood cell, hemoglobin, neutrophil, eosinophil, and platelet counts and mean platelet volume, and higher monocyte counts compared to subacute and chronic subgroups. CONCLUSION: It was noteworthy that in addition to anemia and monocytosis, eosinopenia was third most prominent laboratory findings in the study. Pancytopenia and thrombocytopenia rates were low.


Brucellosis , Humans , Brucellosis/epidemiology , Brucellosis/blood , Brucellosis/complications , Male , Female , Adult , Middle Aged , Turkey/epidemiology , Young Adult , Thrombocytopenia/epidemiology , Thrombocytopenia/blood , Adolescent , Aged , Anemia/epidemiology , Anemia/blood , Anemia/etiology , Blood Cell Count
...